INmune Bio Inc
INMB
查看详细走势图
1.135USD
-0.065-5.42%
收盘 03/30, 16:00（美东）报价延迟15分钟
11.03M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-5.42%
5天
-2.99%
1月
-12.02%
6月
-46.21%
今年开始到现在
-27.24%
1年
-84.91%
查看详细走势图
TradingKey INmune Bio Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
INmune Bio Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名127/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价7.00。中期看，股价处于下降通道。近一个月，市场表现非常差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
INmune Bio Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
INmune Bio Inc亮点
亮点风险
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
业绩增长期
公司处于发展阶段，最新年度总收入14.00K美元
利润高增长
公司净利润处于行业前列，最新年度总收入14.00K美元
估值高估
公司最新PE估值-0.54，处于3年历史高位
机构减仓
最新机构持股4.62M股，环比减少40.69%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值957.85K
活跃度降低
近期活跃度降低，过去20天平均换手率1.74
分析师目标
根据
4
位分析师
买入
评级
7.000
目标均价
+483.33%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
INmune Bio Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
INmune Bio Inc简介
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
公司代码INMB
公司INmune Bio Inc
CEOMoss (David J)
网址https://www.inmunebio.com/
相关品种
